DAX ®11.611,51-1,15%TecDAX ®2.720,50-1,03%Dow Jones25.628,90-2,37%NASDAQ 1007.464,99-3,15%
finanztreff.de

BUSINESS WIRE: Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

| Quelle: Business_Wire | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

FOSTER CITY, Calif. (BUSINESS WIRE) 19.07.2019

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.

Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.

“Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development.

Gilead’s antiviral portfolio includes among the most widely used medicines for the treatment of HIV, hepatitis B and hepatitis C, as well as influenza infection.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that Gilead may fail to advance any of the preclinical antiviral programs licensed from Novartis. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Ryan McKeel, Media
(650) 377-3548

Werbung

Das könnte Sie auch interessieren

Weitere Nachrichten

Quelle: Business_Wire
23.08. BUSINESS WIRE: Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
23.08. BUSINESS WIRE: San Fang Chemical wechselt für den Support seiner Oracle EBS- und Oracle Database-Software zu Rimini Street
23.08. BUSINESS WIRE: Mori Building enthüllt riesiges Projekt zur städtischen Regenerierung von Tokios Innenstadt
23.08. BUSINESS WIRE: Ethereum (ETH) è ora negoziabile sulla piattaforma bitFlyer Buy/Sell BTC/CHF 9.877,8850 -1,1848%
23.08. BUSINESS WIRE: 32 Leading Global Fashion and Textile Companies Make Commitments on Climate, Biodiversity and Oceans KERING S.A. INH. EO 4 423,50 +0,36%
23.08. BUSINESS WIRE: Gravity stellt auf der Gamescom 2019 seine Zukunftspläne vor
23.08. BUSINESS WIRE: Gravity annuncia i suoi piani futuri al Gamescom 2019
23.08. BUSINESS WIRE: Ethereum (ETH) jetzt auch auf “bitFlyer Buy/Sell” handelbar BTC/CHF 9.877,8850 -1,1848%
23.08. BUSINESS WIRE: Mori Building intraprende un imponente progetto di rigenerazione urbana nel centro di Tokyo
23.08. BUSINESS WIRE: STALICLA annuncia il completamento della riunione pre-IND con la FDA su STP1 per il sottogruppo di pazienti con disturbo dello spettro autistico (DSA)
Rubrik: Finanzmarkt
16:53 Bolsonaro wirft das Militär in die Schlacht gegen die Feuersbrunst
16:52 ROUNDUP 3: Neue Zusammenstöße zwischen Polizei und Demonstranten in Hongkong
16:48 Elyséekreise: Irans Außenminister nicht bei eigentlichem G7-Gipfel
16:48 G7/ROUNDUP: Irans Außenminister Sarif kommt überraschend zu Gipfel in Biarritz
16:47 G7/ROUNDUP: USA und Japan einig über Handelsdeal - Unterzeichnung im September
16:40 G7/ROUNDUP: Friedlicher Protest im Baskenland gegen Gipfel
16:40 Klimaschutz in Gebäuden soll stärker gefördert werden DT. WOHNEN 29,40 -1,93%
16:38 Delivery Hero verkauft Blumen, Medizin und Lebensmittel DELIVERY HERO SE NA O.N. 45,03 -0,64%
16:21 ROUNDUP/G7/'Sky': Johnson will bei No-Deal-Brexit deutlich weniger an EU zahlen
16:18 'WSJ': UBS und Deutsche Bank haben Allianz im Investmentbanking geprüft DT. BANK 6,15 +1,42%
Werbung

News-Suche

Suchbegriff:
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 35 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen